The nearer the bar, the greater the chances of risky drinking 
November 2nd, 2012
Bottles of alcohol are seen at The Lord Cardigan pub in east London January 26, 2012. The pub is within a mile of the Olympic Park where the 2012 Olympic Games will take place. Credit: Reuters/Eddie Keogh By Amy Norton NEW YORK | Fri Nov 2, 2012 12:11pm EDT NEW YORK (Reuters Health) – Does living near a bar encourage people to overindulge, or do heavy drinkers move to neighborhoods with easy access to alcohol
[Continue Reading...]
Sanofi draws fire over cost of MS drug Lemtrada
November 1st, 2012
PARIS | Wed Oct 31, 2012 8:03pm EDT PARIS (Reuters) – Medical journal The Lancet warned that Sanofi’s experimental multiple sclerosis drug Lemtrada may be too costly for patients and health insurers once it gets approved by regulators. The journal, which published the encouraging results of two late-stage Lemtrada tests on Thursday, also criticized the drugmaker’s decision to withdraw leukemia therapy Campath, the same drug given at a different dosage, depriving MS patients who had been using it off-label. In an editorial accompanying the test results, The Lancet voiced concerns that Lemtrada would be priced higher than current MS drugs on the market and said the discontinuation of Campath may mean patients who had used it for MS would not be able to continue their treatment
[Continue Reading...]
Eat chocolate, win the Nobel Prize?
October 10th, 2012
By Frederik Joelving NEW YORK | Wed Oct 10, 2012 5:12pm EDT NEW YORK (Reuters Health) – Of all the chocolate research out there, the most unabashed tribute to the “dark gold” has to be a study just published in one of the world’s most prestigious medical journals. Drum roll, please: The higher a country’s chocolate consumption, the more Nobel laureates it spawns per capita, according to findings released today in the New England Journal of Medicine. And guess who leads the pack?
[Continue Reading...]
Trial suggests Prevnar may also protect ages 18-49
October 4th, 2012
Thu Oct 4, 2012 12:42pm EDT (Reuters) – Pfizer Inc said a late-stage trial of its vaccine to protect against pneumococcal bacteria suggested it would also work in adults aged 18-49, thereby possibly expanding its sales. The vaccine, Prevnar 13, which already has $3.5 billion in annual sales from it use by those over age 50 and under age five, is designed to protect against pneumonia, meningitis and other infections caused by pneumococcal bacteria.
[Continue Reading...]
ArQule, Daiichi Sankyo discontinue lung cancer drug trial
October 2nd, 2012
Tue Oct 2, 2012 9:24am EDT (Reuters) – Biotechnology company ArQule Inc and Japan’s Daiichi Sankyo Co Ltd said they will discontinue a late-stage trial of their experimental lung cancer drug after an interim analysis showed it would not meet the main goal of improving overall survival.
[Continue Reading...]
Sanofi to unveil plans for French research shake-up
September 24th, 2012
By Elena Berton PARIS | Mon Sep 24, 2012 12:58pm EDT PARIS (Reuters) – French drugmaker Sanofi will reveal on Tuesday how it plans to shake up its French research operations in a cost-cutting drive which unions predict could mean up to 2,500 layoffs. The French government has criticised Sanofi’s cutback plans when France has rising unemployment, which is predicted to hit more than 3 million for the first time during the economic crisis, official data may show on Wednesday. Industry Minister Arnaud Montebourg, who has sided with the unions, has called the plan “unacceptable.” The mayor of the southern town of Toulouse, which could lose around 600 jobs with the closure of a cancer research centre, has called Sanofi’s top managers “gangsters.” Sanofi employs 28,000 staff in France, representing 25 percent of the company’s total workforce, across 49 sites such as the Paris headquarters, research laboratories, production and distribution facilities.
[Continue Reading...]
Global health group seeks to "save brains" as well as lives
September 13th, 2012
By Kate Kelland LONDON | Thu Sep 13, 2012 4:02am EDT LONDON (Reuters) – As many as 200 million children across the world fail to reach their full potential because their early brain development is held back by poverty, disease and malnutrition, global health experts said on Thursday. Announcing backing for several projects aimed at “saving brains” as well as lives in poorer countries, they said global health and development efforts should focus not only on keeping children alive, but on improving their first 1,000 days. The projects include plans to encourage so-called “kangaroo mother care”, where low-weight newborns are held skin to skin rather than put into incubators, and ways of combating maternal depression to boost interaction between mothers and babies
[Continue Reading...]
France investigating two suspected cases of deadly Yosemite virus
September 5th, 2012
A visitor takes in the view of Upper Yosemite Falls in Yosemite National Park, California May 17, 2009. Credit: Reuters/Robert Galbraith By Ronnie Cohen SAN FRANCISCO | Wed Sep 5, 2012 4:37pm EDT SAN FRANCISCO (Reuters) – Health officials in France were investigating two suspected cases of deadly mouse-borne hantavirus in people who may have been exposed at Yosemite National Park this summer
[Continue Reading...]
U.S. officials sound worldwide alert for Yosemite hantavirus risk
September 5th, 2012
A visitor takes in the view of Upper Yosemite Falls in Yosemite National Park, California May 17, 2009. Credit: Reuters/Robert Galbraith By Ronnie Cohen SAN FRANCISCO | Tue Sep 4, 2012 9:37pm EDT SAN FRANCISCO (Reuters) – U.S.
[Continue Reading...]
Routine screening catches child abuse in ER
August 28th, 2012
By Amy Norton NEW YORK | Tue Aug 28, 2012 12:27pm EDT NEW YORK (Reuters Health) – Routinely screening all children seen in the ER for signs of maltreatment seems to have improved child abuse detection in the Netherlands, a new study finds.
[Continue Reading...]
